A Trial Investigating the Effect of NN5401 in Subjects With Type 2 Diabetes

A Trial Investigating the Pharmacodynamic Response of NN5401 in Subjects With Type 2 Diabetes

This trial is conducted in Europe. The aim of this trial is to evaluate the blood glucose-lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in subjects with type 2 diabetes.

Inclusion Criteria:

• Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months
• Body mass index below or equal to 35.0 kg/m^2

Exclusion Criteria:

• Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
• Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day)
• Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period